**SU2C-Fanconi Anemia Research Fund-Farrah Fawcett Foundation Head and Neck Cancer Research Team:**

“Precision Therapy for Fanconi Anemia and HPV-related Head and Neck Cancers”

In addition to conducting a vaccination clinical trial, the Team has used their epitope-identification technology to find other epitopes for the development of additional immunotherapies.

Progress includes:

**January 2019**
- The amended protocol was accepted, and accrual efforts are underway with a plan to enroll five additional patients.
- Molecular studies have been initiated to analyze the T cell Vb distribution in patient tissue.

**August 2018**
- The team has optimized its clinical trial protocol and is actively recruiting new patients.

**June 2017**
- Techniques to analyze patient samples have been developed. These techniques will facilitate identification of different cells from the patient tissue, including immune cells, and analyses of proteins from patient blood.

**December 2016**
- The clinical trial of the vaccine has opened. Patients with either recurrent and/or metastatic head and neck, cervical or anal cancer can enroll.

**December 2015**
- The Team has acquired state-of-the-art new equipment and is optimizing and refining the sensitivity for detecting specific flags on cells associated with HPV cancers. Detection sensitivity is vital to select the most suitable patient for the trial and for subsequent evaluation of how the vaccine therapy is working.

**December 2014**
- The Team has developed a protocol for their vaccination clinical trial.